麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

Overseas Regulatory Announcement

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.

Set out below is the "ANNOUNCEMENT ON OBTAINING THE U.S. FDA APPROVAL FOR THE COMPANY'S DRUG CETRORELIX ACETATE FOR INJECTION " of Livzon Pharmaceutical Group Inc.* published on the website of the Shenzhen Stock Exchange, which is set out herein for information purpose only.

The abovementioned announcement is prepared in Chinese, if there is any discrepancy between the Chinese version and the English version, the Chinese version shall prevail.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Yang Liang
Company Secretary

Zhuhai, China
26 April 2024

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

* *For identification purpose only*

LIVZON PHARMACEUTICAL GROUP INC. ANNOUNCEMENT ON OBTAINING THE U.S. FDA APPROVAL FOR THE COMPANY'S DRUG CETRORELIX ACETATE FOR INJECTION

Recently, Livzon Group Livzon Pharmaceutical Factory* (麗珠集團麗珠製藥廠), a wholly-owned subsidiary of Livzon Pharmaceutical Group Inc.* (麗珠醫藥集團股份有限公司) (hereinafter referred to as "the Company"), received the approval notice for the ADNA (ANDA number: 214540) issued by the U.S. Food and Drug Administration (hereinafter referred to as "U.S. FDA"), approving the market launch of Cetrorelix Acetate for Injection developed by the Company in the United States. The relevant information is announced as follows:

I. GENERAL INFORMATION OF THE DRUG

Drug name: Cetrorelix Acetate for Injection（注射用醋酸西曲瑞克）

English name/Latin name: Cetrorelix Acetate for Injection

Indications: Inhibition of premature ovulation in patients undergoing controlled ovarian stimulation

Dosage Form: Injection

Specification: 0.25mg/vial

ANDA No.: 214540

Validity: 24 months

Applicant: Livzon Group Livzon Pharmaceutical Factory*

Manufacturer: Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (南京健友生化製藥股份有限公司）

II. OTHER RELEVANT INFORMATION OF THE DRUG

Cetrorelix Acetate for Injection is a third-generation gonadotropin-releasing hormone antagonist (GnRH-ant). Cetrorelix Acetate for Injection has the advantages of rapid onset and low incidence of OHSS and adverse events. The Company's Cetrorelix Acetate for Injection was approved for market launch in China on 31 December, 2021, and registration applications have been submitted in several overseas countries.

As at the disclosure date of this announcement, the accumulated direct research and development costs for Cetrorelix Acetate for Injection amounted to approximately RMB22.9048 million.

III. MARKET CONDITION OF SIMILAR DRUGS

As at the disclosure date of this announcement, Cetrorelix Acetate for Injection from a total of four companies, including the original research company, (including Livzon Group Livzon Pharmaceutical Factory*) have been approved for market launch in the U.S., and Cetrorelix Acetate for Injection from a total of seven companies (including Livzon Group Livzon Pharmaceutical Factory*) have been approved for market launch in China.

Upon enquiry, the global sales amount of Cetrorelix Acetate for Injection in 2022 was approximately US$216.00 million, of which approximately US$105.00 million was from the U.S. market. Pursuant to the data from IQVIA sampling statistics assessment, the domestic terminal sales amount of Cetrorelix Acetate for Injection in 2023 was approximately RMB241.6436 million.

IV. THE IMPACT ON THE COMPANY AND THE RISK WARNING

The Cetrorelix Acetate for Injection obtained the approval from the U.S. FDA, meaning the Company was qualified to sell the product as a drug in the U.S. market, which positively impacts the company's expansion into overseas markets and accumulates valuable experience. As the drug export business is vulnerable to changes in market demand, policy changes, exchange rate fluctuations, market competition and other factors, the sales scale and subsequent expansion progress of the product in the U.S. market are uncertain. Therefore, the investors are advised to invest rationally and pay careful attention to investment risks.

Notice is hereby given.

Board of Directors of Livzon Pharmaceutical Group Inc. *

27 April 2024

** For identification purpose only*